The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population

被引：0
|
作者：
Pei-Yin Pan
Meei-Shyuan Lee
Chin-Bin Yeh
机构：
[1] Tri-Service General Hospital,Department of Psychiatry
[2] National Defense Medical Center,undefined
[3] School of Public Health,undefined
[4] National Defense Medical Center,undefined
来源：
BMC Psychiatry | / 15卷
关键词：
Schizophrenia; Quetiapine XR; Antipsychotic agents; Drug switching; Chinese population;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Effectiveness of Lurasidone in Patients With Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics: A Randomized, 6-Week, Open-Label Study
    McEvoy, Joseph P.
    Citrome, Leslie
    Hernandez, David
    Cucchiaro, Josephine
    Hsu, Jay
    Pikalov, Andrei
    Loebel, Antony
    JOURNAL OF CLINICAL PSYCHIATRY, 2013, 74 (02) : 170 - 179
  • [22] Results from a phase III study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder
    Bandelow, B.
    Bobes, J.
    Ahokas, A.
    Eggens, I.
    Liu, S.
    Brecher, M.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2007, 11 (04) : 314 - 315
  • [23] Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study
    Inagaki, Nobuya
    Sano, Hiroki
    Seki, Yoshifumi
    Kuroda, Shingo
    Kaku, Kohei
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (02) : 354 - 359
  • [24] Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study
    Sanko-Resmer, Joanna
    Boillot, Olivier
    Wolf, Philippe
    Thorburn, Douglas
    TRANSPLANT INTERNATIONAL, 2012, 25 (03) : 283 - 293
  • [25] Safety and Efficacy of Once-Daily Trospium Chloride Extended-release in Male Patients With Overactive Bladder
    MacDiarmid, Scott A.
    Ellsworth, Pamela I.
    Ginsberg, David A.
    Oefelein, Michael G.
    Sussman, David O.
    UROLOGY, 2011, 77 (01) : 24 - 29
  • [26] Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia
    Jarbrink, Krister
    Kreif, Noemi
    Benedict, Agnes
    Locklear, Julie
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (03) : 709 - 716
  • [27] Safety and Tolerability of Once-Daily, Extended-Release Memantine in Patients with Moderate to Severe Alzheimer's Disease: Results of a 52-Week Open-Label Trial
    Meyers, Barnett S.
    Lin, Min
    Graham, Stephen M.
    ANNALS OF NEUROLOGY, 2010, 68 (04) : S49 - S50
  • [28] Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127)
    Wallace, Mark
    Skowronski, Roman
    Khanna, Sarita
    Tudor, Lulia Cristina
    Thipphawong, John
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (05) : 981 - 989
  • [29] Long-Term, Open-Label Safety and Tolerability Study of Once-Daily Extended-Release Oxcarbazepine (SPN-804) as Adjunctive Therapy in Patients with Refractory Partial Seizures
    Johnson, Janet
    Brittain, Scott
    Louro, Dawn
    NEUROLOGY, 2013, 80
  • [30] Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, open-label study in stable patients switched from typical and atypical oral antipsychotics
    Cetin, M
    Ebrinc, S
    Basoglu, C
    Semiz, UB
    Gunay, H
    Iyisoy, MS
    Ergun, BM
    Gunes, C
    Sahan, A
    Oguz, M
    Noyan, O
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S134 - S135
12345